Variables which might predict the response to salvage radiotherapy in chinese patients with biochemical failure after radical prostatectomy.
OBJECTIVE
To evaluate the relationship between the variables and the outcomes of salvage radiotherapy (sRT) to find some predictors of sRT.


METHODS
The medical records of 56 patients receiving sRT for biochemical failure after radical prostatectomy (RP) were available for retrospective review. sRT was defined as external beam radiotherapy for patients with a continuous increase in the prostate-specific antigen (PSA) level of >or=0.2 ng/ml after RP. Response was defined as achievement of a PSA nadir of <or=0.1 ng/ml.


RESULTS
The mean follow-up period after sRT was 31.6 months. The predictors of response to sRT were PSA doubling time (PSADT) and seminal vesicle invasion. The median PSADT in responders was 6.5 months versus 4.0 months in non-responders (OR=1.66, p=0.006). The patients with a PSADT of >6 months were all responders. The response rate in patients with seminal vesicle invasion was 42.9% (6/14) versus 76.2% (32/42) in patients without seminal vesicle invasion (OR=0.119, p=0.015).


CONCLUSIONS
PSADT and the state of seminal vesicle invasion were good predictors of response to sRT. sRT was especially effective when the PSADT was >6 months and in patients without seminal vesicle invasion.
Xu
Y
Y
Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.
Liu
R
R
Zhang
Z
Z
Hao
Q
Q
Qi
S
S
Li
J
J
Teng
Z
Z
D002681:China / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000453:epidemiology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D017211:Treatment Failure
D017430:Prostate-Specific Antigen